Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial

Prior treatment

• (3) Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator.
• (4) Intolerance to anticoagulant or antiplatelet therapies or any other peri/postoperative therapy the investigator will require based on the patient's health status.
• (12) Pulmonary embolism and pulmonary artery systolic blood pressure exceeding 60mmHg within 3 weeks prior to enrollment combined with at least one of the following 2 parameters demonstrating that pulmonary vascular resistance did not respond to drug therapy: Pulmonary vascular resistance greater than 8 wood units; The transpulmonary differential pressure exceeds 20mmHg.

Other illness

• (1) Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy pericardial disease, amyloidosis, or restrictive cardiomyopathy.
• (7) Presence of moderate to severe aortic insufficiency or a history of the mechanical aortic valve that will not be converted to a bioprosthesis or oversewn at the time of implantation.
• (8) History of any organ transplantation.
• (11) History of severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease or a diagnosis of primary pulmonary hypertension.
• (14) Presence of severe peripheral vascular disease with resting pain or extremity ulceration.
• (15) Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and Left Ventricular Assist System management, or brain death from various causes.
• (16) Expect to live less than 1 year due to malignant tumor or other diseases.

Lab values

• (2) Presence of an active, uncontrolled infection confirmed by a combination of clinical symptoms and laboratory tests.
• (10) TBIL (total bilirubin) \> 3.0 mg/dL, serum creatinine (SCr) \> 3.0 mg/dL within 48 hours prior to LVAD implantation surgery or may require dialysis.

Other

• (5) Patients require bi-ventricular assist device support.
• (6) Pregnancy.
• (9) Presence of uncorrected thrombocytopenia or severe coagulopathy, such as diffuse intravascular coagulation.
• (13) Established and untreated abdominal or thoracic aortic aneurysm \> 5cm in diameter.
• (17) Participation in any other clinical trials that may influence the results of this study.
• (18) Other circumstances that are unforeseen and determined by the researcher to be unsuitable.

• (1) Age ≥ 18 years.
• (2) The patient or legal representative has signed the Informed Consent Form (ICF).
• (3) Body Surface Area (BSA) ≥ 1.0 m\^2.
• (4) Females of childbearing age must agree to use adequate contraception.
• (5) Patients with NYHA Class IV heart failure symptoms who have failed to be reversed by previous standardized oral treatment with anti-heart failure drugs (ACEI, beta-blockers, and diuretics).
• (6) Left Ventricular Ejection Fraction (LVEF) ≤ 30%, and at least one of the following conditions occurs:
• a. Fail to be reversed by or be weaned from intra-aortic balloon pump (IABP), extracorporeal membrane oxygenator (ECMO), or other short-term mechanical circulatory support;
• b. Rely on continuous intravenous administration of one or more vasoactive or inotropic drugs;
• c. Meeting the diagnostic criteria of cardiogenic shock: blood pressure \< 90/60mmHg, cardiac index \< 2.0 L/min/m\^2, and pulmonary capillary wedge pressure \> 18mmHg.